Skip to content

Dopamine D2 Receptor Blockade by Antipsychotics and Maintenance of Remission in Schizophrenia

Dopamine D2 Receptor Blockade by Antipsychotics and Maintenance of Remission in Schizophrenia - D2 Receptor Blockade and Remission in Schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006011
Enrollment
60
Registered
2011-08-01
Start date
2011-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

continuous D2 blockade of &gt
65%. Subjects will be treated with an individually prepared regimen and observed for one year. Intermittent D2 blockade of &gt
65%. Subjects will be treated with an individually prepared regimen and observed for one year.

Sponsors

Keio University, School of Medicine Department of Neuropsychiatry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) DSM-IV diagnosis of schizophrenia or schizoaffective disorder (2) Having received a stable dose of risperidone or olanzapine for previous 3 months

Exclusion criteria

Exclusion criteria: (1) Receiving another antipsychotic drug (2) History of treatment with long-acting risperidone within 6 months (3) Past history of vagus nerve reflection with a blood test

Design outcomes

Primary

MeasureTime frame
Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), Japanese version of the Calgary Depression Scale for Schizophrenics (JCDSS), Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J)

Secondary

MeasureTime frame
Clinical Global Impression–Schizophrenia (CGI-SCH), Global Assessment of Functioning (GAF)

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026